Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Jagath R. Junutula, Helga Raab, Suzanna Clark, Sunil Bhakta, Douglas D. Leipold, Sylvia Weir, Yvonne Chen, Michelle Simpson, Siao Ping Tsai, Mark S. Dennis, Yanmei Lu, Y. Gloria Meng, Carl Ng, Jihong Yang, Chien C Lee, Eileen Duenas, Jeffrey Gorrell, Viswanatham Katta, Amy Kim, Kevin S. McDorman(Charles River Laboratories (Netherlands)), Kelly M. Flagella, Rayna Venook, Sarajane Ross, Susan D. Spencer, Wai Lee Wong, Henry B. Lowman, Richard Vandlen, Mark X. Sliwkowski, Richard H. Scheller, Paul Polakis, William Mallet
Nature Biotechnology
July 20, 2008
10.1038/nbt.1480
Cited by 1,344

Abstract

Related Papers

Monoclonal antibody therapy of cancer
Gregory P. Adams, Louis M. Weiner|Nature Biotechnology|2005|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al.|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
Anna M. Wu, Peter D. Senter|Nature Biotechnology|2005|1k
Cathepsin B-Labile Dipeptide Linkers for Lysosomal Release of Doxorubicin from Internalizing Immunoconjugates:  Model Studies of Enzymatic Drug Release and Antigen-Specific In Vitro Anticancer Activity
Gene M. Dubowchik, Raymond A. Firestone, Linda Padilla et al.|Bioconjugate Chemistry|2002|544
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Michael Sun, Kevin S. Beam, Charles G. Cerveny et al.|Bioconjugate Chemistry|2005|364